NCT04241835 2026-04-16
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Ipsen
Phase 1 Terminated
Clinical Trials
2,125 trialsNCT06066424 2026-04-16
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06082960 2026-04-16
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Gilead Sciences
Phase 1 Active not recruiting
NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06625593 2026-04-16
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07380334 2026-04-16
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Recruiting
NCT07533708 2026-04-16
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT05718895 2026-04-15
CLINCH
Antengene Corporation
Phase 1 Recruiting
NCT06233942 2026-04-15
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06596473 2026-04-15
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07181681 2026-04-15
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07226349 2026-04-15
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07362888 2026-04-15
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
Adcendo ApS
Phase 1 Recruiting
NCT07395258 2026-04-15
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Recruiting
NCT07529535 2026-04-15
A Phase I/II Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1 Suspended
NCT04375267 2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1 Completed
NCT05071846 2026-04-14
MVX-ONCO-2 in Advanced Solid Tumors
University Hospital, Geneva
Phase 1 Active not recruiting
NCT05155332 2026-04-14
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Recruiting
NCT05430373 2026-04-14
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
Grit Biotechnology
Phase 1 Recruiting
NCT06220864 2026-04-14
SNV1521 in Participants With Advanced Solid Tumors
Synnovation Therapeutics, Inc.
Phase 1 Recruiting
NCT06718621 2026-04-14
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT01434316 2026-04-13
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02453620 2026-04-13
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04491942 2026-04-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05879627 2026-04-13
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Bio-Thera Solutions
Phase 1 Terminated
NCT06143774 2026-04-13
Study of TRX-920 for Patients With Advanced Solid Tumors
TaiRx, Inc.
Phase 1 Recruiting
NCT06352359 2026-04-13
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
OncoC4, Inc.
Phase 1 Recruiting
NCT06573294 2026-04-13
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
Genmab
Phase 1 Recruiting
NCT06960395 2026-04-13
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT07040943 2026-04-13
Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
West China Hospital
Phase 1 Recruiting
NCT07223125 2026-04-13
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT07408258 2026-04-13
Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
OncoC4, Inc.
Phase 1 Not yet recruiting
NCT07524348 2026-04-13
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Samsung Bioepis Co., Ltd.
Phase 1 Recruiting
NCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06672523 2026-04-09
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
Bristol-Myers Squibb
Phase 1 Recruiting
NCT06832982 2026-04-09
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
Shanghai Pushi Medical Science Co. Ltd
Phase 1 Recruiting
NCT07141706 2026-04-09
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1 Recruiting
NCT07190833 2026-04-09
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
Phase 1 Recruiting
NCT06057038 2026-04-08
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
Phase 1 Active not recruiting
NCT06892379 2026-04-08
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT05571839 2026-04-07
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen Inc.
Phase 1 Active not recruiting
NCT05861895 2026-04-07
HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
HighField Biopharmaceuticals Corporation
Phase 1 Recruiting
NCT06444815 2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1 Recruiting
NCT07170592 2026-04-07
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Bionoxx Inc.
Phase 1 Not yet recruiting
NCT07443020 2026-04-07
RIOT 4B
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 1 Recruiting
NCT06014502 2026-04-06
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
ImmunoGenesis
Phase 1 Recruiting
NCT06422520 2026-04-06
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT06773091 2026-04-06
NKSOLID
Shanghai NK Cell Technology Co., LTD
Phase 1 Recruiting
NCT06031441 2026-04-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT06619587 2026-04-03
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Recruiting